LAG3 and head and neck cancer: Similarly, in another study on imaging LAG-3 expression (89Zr-BI 754111) in NSCLC and head and neck cancer patients with progressive disease following PD-1 therapy, tumour heterogeneity in tracer uptake, and discrepancies between high tracer uptake and low LAG-3 expression on tumour biopsy were observed [55].